Meropenem-Vaborbactam is a combination drug of a Carbapenem and a beta-lactamase inhibitor with enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases. Tiziana Di Martino, Chief Medical Officer at Q-linea commented: “Meropenem-Vaborbactam is a very interesting drug which can help to treat critically ill patients, especially when certain resistance mechanisms are present. We had many customer interactions where this antibiotic has been raised as a strong wish to be included on the panel and are very glad to be able to add it on. One of the strengths of ASTar is the capacity of 336 wells we are having on our disk, and this enables us to add this new drug without compromising on any previously present antibiotic or dilution range, so it is true added value for our customers and their patients.”     

“This is an important step in our continuous strive to offer the best product for our customers. The use of antibiotic combinations has become increasingly important for treatment and Meropenem-Vaborbactam is another important addition to our panel to fight resistant bacteria. We believe that the addition will be well received by our customers helping them providing the best possible treatment for patients with blood stream infections,” said Jonas Jarvius, CEO and President at Q-linea.